Walsh & Associates’s Amgen AMGN Stock Holding History

Walsh & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90.5K	Hold	250	–	–	0.07%	93
2026 Q1	$88K	Hold	250	–	–	0.09%	87
2025 Q4	$81.8K	Buy	+250	New	+$79.3K	0.08%	87

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Walsh & Associates's AMGN Position: Q2 2026 in Review

Walsh & Associates held its Amgen (AMGN) position steady in Q2 2026 at 250 shares worth $90.5K. The position accounts for 0.07% of the portfolio, ranked #93.

Walsh & Associates first reported a position in AMGN in Q4 2025 and has held it in 3 quarters since. 3,132 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Walsh & Associates held 250 shares of Amgen worth $90.5K as of Q2 2026.
Walsh & Associates left its Amgen share count unchanged in Q2 2026.
Amgen made up 0.07% of Walsh & Associates's portfolio in Q2 2026, its #93 holding.
Walsh & Associates first reported a position in Amgen in Q4 2025 and has held it in 3 quarters since.
3,132 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.